Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
KalVista Pharmaceuticals
KalVista Pharmaceuticals
Activities:
Manufacturing
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
The (r)evolution of biocatalysis in API synthesis
Explore Farmhispania Group’s enzyme toolbox to develop cost-effective, green-by-design synthetic routes for the cGMP production of your small-molecule NCEs
From batch to continuous chemistry to continuous processing
The main challenge in many flow reactors lies in achieving a smooth and continuous flow within microchannels. Dec Group focuses on effectively transporting solid materials and...
PCI Pharma Services commences installation of sterile fill-finish and lyophilisation line
The Bedford, NH site will advance PCI's manufacturing capabilities with twin lyophilisers and a large-scale isolator filling line, making this the third sterile fill-finish...
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Medical breakthroughs on the horizon with a UK research boost of £32m
Since 2011 there has been a total investment of £350m, split equally between the MRC, Innovate UK and leveraged funding from industry
Research & Development
KalVista Pharmaceuticals joins European consortium focused on novel eye treatments
Consortium supported by €1.66m grant from EU Seventh Framework Programme
Research & Development
KalVista seals £8m funding for DME research
UK firm focuses on small molecule plasma kallikrein inhibitors
Subscribe now